Navigation Links
Fingerprinting prostate cancer

Two new genes which are active in prostate cancer have been identified by US researchers. At a molecular level, cancer tissue differs markedly from normal healthy tissue in its pattern of gene activity. Researchers have now developed the tools that can visualise analyse these 'molecular fingerprints' that characterise the cancerous cell. Using microarray technology, it's now possible to analyse thousands of genes in one experiments.//

Doctors at the University of Michigan have now produced the first ever molecular fingerprint of prostate cancer. They examined more than 700 prostate tissue samples from more than 50 men - covering normal tissue, tissue with benign change, and also tissues from both localised and aggressive prostate cancer. They found that more than 200 genes were expressed differently between normal and cancer tissue. Of these, some are already known to be involved in cancer, while others were completely new.

Of particular interest were two genes - hepsin and pim-1. The highest levels of hepsin were found in pre-cancerous tissue just before cancer develops, and the lowest in benign prostate tissue. Hepsin play a main role in tumour development. Pim-1, a known cancer-causing gene, was also highly expressed in prostate cancer tissue. Levels of hepsin and Pim-1 were significantly linked to prognosis, when the men's clinical histories were checked.

The researchers say that the discovery of prostate cancer's molecular fingerprint could lead to many new diagnostic tests. These could offer more to the patient than the current PSA (prostate specific antigen) test and can be used as a useful diagnostic tool.


'"/>




Page: 1

Related medicine news :

1. Better prostate cancer detection
2. Protective effects of tomatoes in prostate cancer
3. Early detection of prostate cancer
4. No link between blood groups and prostate cancer
5. Cure for osteoporosis in prostate cancer patients
6. Novel biopsy technique for prostate cancer
7. New diagnostic marker for prostate cancer
8. Inadequate proof to justify routine prostate screen
9. Combination regime may work against prostate cancer
10. Lifestyle linked to prostate cancer risk
11. Finasteride lowers risk of prostate cancer but increases risk of high-grade tumors
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:4/29/2016)... , ... April 29, 2016 , ... ... loans more flexibility in repaying their loans, more information about their loan terms ... when total outstanding student loan debt, including federal and private loans, has reached ...
(Date:4/29/2016)... Petersburg, Fla. (PRWEB) , ... April 29, 2016 ... ... Children’s Hospital surgeon reveals that infants born with severe congenital diaphragmatic hernia have ... babies is born with congenital diaphragmatic hernia (CDH)—a condition where the diaphragm fails ...
(Date:4/29/2016)... ... April 29, 2016 , ... Mobility Designed is redefining mobility with ... armpits, the M+D Crutch evenly distributes body weight from the elbow to the forearm. ... using the crutches than with other crutches. , Co-founders Max and Liliana Younger were ...
(Date:4/29/2016)... ... , ... Melanoma is the deadliest type of skin cancer. Although only about 1 percent of ... deaths. More than 10,000 people are expected to die of melanoma this year. The risk ... one of the most commonly diagnosed cancers in young women. A recent breakthrough in genetic ...
(Date:4/29/2016)... ... , ... Reltok Nasal Products proudly announces that Boston Medical Products, Inc., a ... throat specialty, has added the KOTLER NASAL AIRWAY™ to its diverse product line. , ... patented safety device secured by nasal surgeons onto the floor of the nasal passages, ...
Breaking Medicine News(10 mins):
(Date:4/28/2016)... , April 28, 2016 ... Review, H1 2016" is a report that provides ... helps strengthen R&D pipelines by identifying new targets ... Company Profiles discussed in this H1 ... Farmaceutiche Riunite Srl, AbbVie Inc., Abiogen Pharma S.p.A., ...
(Date:4/27/2016)... Italy , April 27, 2016 ... linear accelerator (MR-linac) platform will be the focal point ... meeting of the European Society for Radiotherapy & Oncology, ... Elekta,s MR-linac integrates a state-of-the-art radiotherapy system and a ... physician to clearly see the patient,s anatomy in real ...
(Date:4/27/2016)... April 27, 2016 Shire plc (LSE: ... Poulton , Chief Financial Officer, will present at the Deutsche ... MA on Wednesday, May 04, 2016, 10:00 am ... be available on the Presentations and Webcasts section of Shire,s ... the webcast will be available on this same website for ...
Breaking Medicine Technology: